Literature DB >> 18520532

Cytokines and coronary artery disease: the state of the art.

Ayman A El-Menyar1.   

Abstract

Initiation and progression of coronary atherosclerosis has been associated with inflammation and cytokines balance. The objective of this study is to understand the role of cytokines in the pathophysiology and management of coronary artery disease. Coronary artery disease has been revisited with revision of the pertinent published articles in the Medline, Scopus, and EBSCO Host research from 1987 to 2007. The 2 groups of cytokines (proinflammatory and anti-inflammatory) have been detected in human atherosclerotic plaques. The balance between the 2 groups may reflect the intensity of occult plaque inflammation and the vulnerability to rupture. Multiple studies have determined that a diverse set of proinflammatory biomarkers can furnish prognostic information beyond the traditional risk factors. Inflammatory responses after coronary revascularization are known to play key role in vascular lesion formation early in atherosclerosis and restenosis. Clinical utilization of cytokines remains promising yet incompletely explored and need more studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18520532     DOI: 10.1097/HPC.0b013e31816713d9

Source DB:  PubMed          Journal:  Crit Pathw Cardiol        ISSN: 1535-2811


  2 in total

1.  Serum profiles of monocyte chemoattractant protein-1 as a biomarker for patients recovering from myocardial infarction.

Authors:  Katarzyna Korybalska; Małgorzata Pyda; Stefan Grajek; Magdalena Lanocha; Andrzej Breborowicz; Janusz Witowski
Journal:  Clin Res Cardiol       Date:  2010-02-07       Impact factor: 5.460

2.  Relationship between serum cytokines receptors and matrix metalloproteinase 9 levels and coronary artery disease.

Authors:  Seyed Reza Mirhafez; Amir Avan; Mohammad Tajfard; Shabnam Mohammadi; Mohsen Moohebati; Arash Fallah; Hamed Ghazavi; Hossein Savadi; Majid Ghayour Mobarhan
Journal:  J Clin Lab Anal       Date:  2016-12-02       Impact factor: 2.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.